LON:IMM ImmuPharma Interim Earnings Report GBX 3.74 +0.34 (+9.82%) As of 11:58 AM Eastern ProfileEarnings History ImmuPharma EPS ResultsActual EPS-GBX 0.38Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuPharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuPharma Announcement DetailsQuarterInterimDate8/6/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile ImmuPharma Earnings HeadlinesImmuPharma appoints Kymos as third Kapiglucagon partner in build towards clinicAugust 10, 2026 | uk.finance.yahoo.comImmuPharma selects Kymos to support Kapiglucagon diabetes development programmeAugust 10, 2026 | uk.finance.yahoo.comThe New Kings of CantillonIn 1720, Richard Cantillon discovered that new money never spreads evenly through an economy. It reaches certain hands first and everyone else pays for it later. Fifty years after the petrodollar reshaped global wealth, a new monetary reset may be underway, this time tied to critical minerals, energy, and AI infrastructure. Stocks like Vertiv, GE Vernova, Arista Networks, and Taseko Mines have already posted major gains since the shift began. Porter Stansberry breaks down the full story, including which companies sit closest to the new money flow.August 26 at 1:00 AM | Porter & Company (Ad)Thermo Fisher (TMO) Lands ImmuPharma Kapiglucagon Diabetes Manufacturing RoleJuly 24, 2026 | finance.yahoo.comImmuPharma appoints Bachem to manufacture key ingredient for diabetes drugJune 25, 2026 | uk.finance.yahoo.comImmuPharma flags Murcia research into P140 as potential brain cancer treatmentJune 24, 2026 | uk.finance.yahoo.comSee More ImmuPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuPharma and other key companies, straight to your email. Email Address About ImmuPharmaImmuPharma (LON:IMM) (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.View ImmuPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-RaisePhotronics Is Quietly Becoming a Key Winner From the AI BoomOpenAI’s Jalapeño Chip Could Change the AI Hardware RaceHONA: The Spin-Off Story the Market Is Reading WrongPDD Beat Earnings—So Why Did the Stock Still Fall?Marzetti Stock Confirms Reversal on Earnings Strength, Dividend GrowthDICK's Sporting Goods Faces Pain Now for a Bigger Prize Upcoming Earnings Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
